We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals
IONS

390 hedge funds and large institutions have $7.29B invested in Ionis Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 69 funds opening new positions, 116 increasing their positions, 131 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 69 | Existing positions closed: 43

6% more funds holding

Funds holding: 369 → 390 (+21)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

0% less capital invested

Capital invested by funds: $7.3B → $7.29B (-$9.2M)

0.96% less ownership

Funds ownership: 86.79% → 85.83% (-0.96%)

11% less repeat investments, than reductions

Existing positions increased: 116 | Existing positions reduced: 131

13% less call options, than puts

Call options by funds: $89M | Put options by funds: $103M

Holders
390
Holders Change
+21
Holders Change %
+5.69%
% of All Funds
7.68%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
69
Increased
116
Reduced
131
Closed
43
Calls
$89M
Puts
$103M
Net Calls
-$13.9M
Net Calls Change
-$11.1M

Top Buyers

1
BI
BVF Inc
California
+$74.1M
2
Rockefeller Capital Management
Rockefeller Capital Management
New York
+$29M
3
Citadel Advisors
Citadel Advisors
Florida
+$24.9M
4
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$22.3M
5
JP Morgan Chase
JP Morgan Chase
New York
+$19.2M

Top Sellers

1
ClearBridge Investments
ClearBridge Investments
New York
-$80M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$60M
3
WRF
Waddell & Reed Financial
Kansas
-$59M
4
APG Asset Management
APG Asset Management
Netherlands
-$26.3M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$22.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$38.8M -$1.15M -19,220 -3%
Charles Schwab
27
Charles Schwab
California
$36.1M +$544K +9,126 +2%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$34.7M +$1.58M +26,539 +5%
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$33.2M -$16.7M -280,132 -34%
JP Morgan Chase
30
JP Morgan Chase
New York
$32.4M +$19.2M +321,660 +149%
Goldman Sachs
31
Goldman Sachs
New York
$32.3M -$2.1M -35,203 -6%
Rockefeller Capital Management
32
Rockefeller Capital Management
New York
$29.6M +$29M +485,973 +13,213%
N
33
Nuveen
North Carolina
$28.8M -$1.31M -22,028 -4%
Mitsubishi UFJ Trust & Banking
34
Mitsubishi UFJ Trust & Banking
Japan
$28.6M -$133K -2,235 -0.5%
Citadel Advisors
35
Citadel Advisors
Florida
$28.2M +$24.9M +417,717 +848%
NAMA
36
Nikko Asset Management Americas
New York
$25.7M +$3.61M +60,592 +17%
Swiss National Bank
37
Swiss National Bank
Switzerland
$25.4M -$1.15M -19,300 -4%
SA
38
Sicart Associates
New York
$24.8M +$16.4K +275 +0.1%
Legal & General Group
39
Legal & General Group
United Kingdom
$24.6M +$976K +16,386 +4%
TAM
40
Tocqueville Asset Management
New York
$24.3M -$447K -7,510 -2%
Stifel Financial
41
Stifel Financial
Missouri
$23.5M -$1.01M -16,960 -4%
RCAMU
42
Rothschild & Co Asset Management US
Connecticut
$22.6M +$7.59M +127,346 +52%
UBS AM
43
UBS AM
Illinois
$21.4M +$972K +16,312 +5%
Deutsche Bank
44
Deutsche Bank
Germany
$20.3M +$8.31M +139,513 +71%
Dimensional Fund Advisors
45
Dimensional Fund Advisors
Texas
$18.3M +$1.36M +22,744 +8%
California Public Employees Retirement System
46
California Public Employees Retirement System
California
$18.3M +$672K +11,282 +4%
AGA
47
Altrinsic Global Advisors
Connecticut
$16.4M -$1.05M -17,630 -6%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$16.2M -$174K -2,915 -1%
Franklin Resources
49
Franklin Resources
California
$15.9M – – –
CS
50
Candriam SCA
Luxembourg
$15.8M -$1.88M -31,500 -11%
1
2
3 4 5

IONS Hedge Fund Activity: Q4 2019 in Review

390 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2019, worth a combined $7.29B — down 0.13% from $7.3B a quarter earlier.

Buyers outnumbered sellers: 69 funds opened new IONS positions and 43 closed out — a net gain of 26 holders — while 116 added to existing stakes and 131 trimmed.

The largest buyer was BVF Inc, adding an estimated $74.1M. The largest seller was ClearBridge Investments, cutting an estimated $80M.

  • 390 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2019, up from 369 in Q3 2019.
  • Funds reported $7.29B of Ionis Pharmaceuticals stock for Q4 2019, down 0.13% quarter-over-quarter.
  • 69 funds opened new Ionis Pharmaceuticals positions in Q4 2019 and 43 closed out, a net change of +26 holders.
  • The largest Ionis Pharmaceuticals buyer in Q4 2019 was BVF Inc, an estimated $74.1M added.
  • The largest Ionis Pharmaceuticals seller in Q4 2019 was ClearBridge Investments, an estimated $80M sold.

Based on aggregated 13F filings for Q4 2019.